Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Diabetes Technol Ther. 2010 Nov;12(11):901-6. doi: 10.1089/dia.2010.0075. Epub 2010 Sep 30.
This study assessed patient-reported outcomes (PRO) for patients with type 2 diabetes treated by insulin pump therapy.
This 16-week, open-label, multicenter study was conducted with adults (averaging 57 years old, 50% women, 68% white non-Hispanic, with duration of diabetes of 13 years) treated at baseline with oral antidiabetes agents (OAD) only (OAD cohort, n = 17), basal insulin with or without OAD (Basal cohort, n = 17), or multiple daily injections (MDI) with or without OAD (MDI cohort, n = 20). All diabetes medications except metformin were discontinued at baseline, and insulin pump therapy was initiated. PRO were measured at baseline and end of study using two measures of health-related quality of life (QOL)--the Diabetes Symptom Checklist-Revised (DSC-R) and the EuroQol-5 Dimensions (EQ-5D)--and a measure of treatment satisfaction--the Insulin Delivery System Rating Questionnaire (IDSRQ).
The combined study population (n = 54) experienced significant reductions in DSC-R total symptoms, as well as a significant increase in the EQ-5D Visual Analog Scale score. The OAD cohort experienced no changes in any QOL measure; the Basal and MDI cohorts each experienced significant improvements in several QOL measures. The combined study population experienced significant improvements in all IDSRQ measures except treatment interference, for which change was not significant. The OAD cohort experienced significant improvements in perceived clinical efficacy and overall treatment preference; the Basal and MDI cohorts each experienced significant improvements in five of the seven IDSRQ measures.
Insulin pump therapy improved QOL and treatment preference in patients with type 2 diabetes.
本研究评估了接受胰岛素泵治疗的 2 型糖尿病患者的患者报告结局（PRO）。
这是一项为期 16 周、开放标签、多中心研究，纳入了成年人（平均年龄 57 岁，50%为女性，68%为白种非西班牙裔，糖尿病病程 13 年），他们在基线时仅接受口服抗糖尿病药物（OAD）治疗（OAD 队列，n=17）、基础胰岛素联合或不联合 OAD（基础队列，n=17）或多次每日注射（MDI）联合或不联合 OAD（MDI 队列，n=20）。所有除二甲双胍以外的糖尿病药物均在基线时停用，并开始胰岛素泵治疗。使用两种健康相关生活质量（QOL）测量方法——糖尿病症状清单修订版（DSC-R）和欧洲五维健康量表（EQ-5D）——以及治疗满意度测量方法——胰岛素输送系统评分问卷（IDSRQ），在基线和研究结束时测量 PRO。
联合研究人群（n=54）的 DSC-R 总症状显著减轻，EQ-5D 视觉模拟评分显著增加。OAD 队列的任何 QOL 测量均无变化；基础和 MDI 队列的 QOL 多项测量均有显著改善。联合研究人群的所有 IDSRQ 测量均有显著改善，除治疗干扰外，变化无统计学意义。OAD 队列在感知临床疗效和总体治疗偏好方面有显著改善；基础和 MDI 队列在 IDSRQ 的七个测量中有五个均有显著改善。
胰岛素泵治疗改善了 2 型糖尿病患者的 QOL 和治疗偏好。
